Recent studies have converged on the overlap of glucagon-like peptide-1|glucose-dependent insulinotropic polypeptide|glucagon receptor agonist therapies and dopamine neurotransmission. While GIP activators are widely employed for addressing type 2 diabetes mellitus, their emerging effects on reward circuits, specifically influenced by DA networks,